CTRI/2022/04/042009
Completed
Phase 2
A double-blind, randomized, placebo-controlled efficacy trial of individualized homoeopathic medicines in treatment of nocturnal enuresis
D N De Homoeopathic Medical College and Hospital0 sites140 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: N394- Other specified urinary incontinence
- Sponsor
- D N De Homoeopathic Medical College and Hospital
- Enrollment
- 140
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients suffering from nocturnal enuresis since at least 3 months
- •2\. Age 5\-18 years
- •3\. Patients of either sex.
- •4\. Literate patients; ability to read English, Hindi and/or Bengali
- •5\. Providing with written informed consent/assent
Exclusion Criteria
- •1\. Patients having any anatomical and/or surgical changes leading to enuresis
- •2\. Patients taking any systemic antibiotics in the past one month.
- •3\. Vulnerable population – unconscious, ambulatory, too sick for consultation, differently abled, terminally or critically ill patients, mentally incompetent people
- •4\. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life\-threatening illness affecting quality of life or any organ failure
- •5\. Patients with a habit of tobacco chewing and /or smoking, alcoholism and/or any form (s) of substance abuse and/or dependence
- •6\. Self\-reported immune\-compromised state
- •7\. Already undergoing homeopathic treatment for chronic disease within last 6 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Homeopathic treatment of geriatric depressioHealth Condition 1: null- DepressionHealth Condition 2: F339- Major depressive disorder, recurrent, unspecifiedCTRI/2017/03/008078MBHM College Hospital MHM College Hospital The CHM College Hospital
Active, not recruiting
Not Applicable
A double-blind, placebo-controlled, randomized efficacy and safety study of levetiracetam extended release formulation (LEV XR), administered as 2 x 500 mg LEV XR tablets once daily as add-on therapy in subjects from 12 to 70 years with refractory epilepsy suffering from partial onset seizuresEUCTR2006-000987-10-FICB S.A.130
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic Idiopathic UrticariaEUCTR2005-002749-38-BEBarrier Therapeutics nv48
Completed
Phase 2
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic urticaria10002426NL-OMON30213Barrier Therapeutics16
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaEUCTR2005-002749-38-CZBarrier Therapeutics nv48